Abstract:Glaucoma research in China has been booming in recent years. The research involves from gene mapping and functional assessment to surgical treatment using phaco alone, trabeculectomy or phaco-trabeculectomy in angle closure glaucoma.1,2 The Panel of Glaucoma of the Chinese Ophthalmological Society has established the diagnosis and classification system for glaucoma with reference to the Preferred Practice Pattern (PPP) introduced by the American Academy of Ophthalmology in 2005. This effort enforces the improvement of the evidence-based classification system.3 Neuroprotection and optic nerve regeneration by stem cells and tissues engineering, and bleb fibrosis modulation using transgene and RNAi techniques have been the focus of forefront research in addition to the increased number of epidemiological studies over the years.4-7 The data suggest a changed spectrum of the disease.8-10 In collaboration with the British and American colleagues, ophthalmologists of the Department of Preventive Ophthalmology, Zhongshan Ophthalmic Center conducted a glaucoma survey in adult residents aged 50 years in Guangzhou. In 1405 of 1864 subjects, 53 were glaucoma cases. In these cases, 21 had primary angle closure glaucoma (PACG), 29 primary open angle glaucoma (POAG), suggesting a prevalence of 3.8%. The survey indicated that POAG is as common as PACG. The current status of glaucoma research in China can be characterized by an increasing number of papers published in international peer-reviewed journals, which provide some insights into this field in China. Definitely, we have a long way to go in clinical and basic studies of the disease. We have the largest population of angle closure glaucoma patients in the world, but the research in this field is not outstanding, especially in epidemiology using international standard, early diagnostic technology, novel surgery and medication, gene therapy, animal modeling, natural artificial vision, etc. In future, what are the priorities given to the research areas in China? The foremost is the establishment of the evidence-based system for diagnosis, prevention and treatment of glaucoma, which is suitable to areas or districts with different socioeconomic status and medical resources. The system is derived from evidence of large-scale, prospective, multi-center clinical trials and population-based studies. Besides, the association of central corneal thickness and intraocular pressure (IOP) needs to be confirmed in addition to the clinical significance of long- or short-term fluctuation, diurnal variation of IOP, individual pressure, target pressure in the glaucoma control. Imaging technology in the early diagnosis and prognosis of glaucoma is considered as important as novel filtration surgery using EX-PRESS miniature drainage implant, SOLX Gold Micro-shunt, without filtering bleb and wound healing modulation using a siRNA nanotechnology delivery system, which have been improved successful in glaucoma surgery. The diversified gene pools of people in China offer a great opportunity for effective gene mapping and its functional study. Application of functional magnetic resonance and two-photon excitation laser scanning microscopy techniques to detect changes in the retina, LGN and visual cortex is promising in unveiling the contribution of the visual pathway to the mechanism of glaucoma. Natural glaucoma experiment model using primates, which is the ideal way to mimic the development and natural history of glaucoma, hopefully offers a unique approach to selecting optimal treatment strategies. Stem cell and tissue engineering are new areas for the neuroprotection and regeneration of optic nerve damage from glaucoma. Sub-retinal or pre-retinal implantation of artificial vision prosthesis assisted by computer chip technology will help to recover partial visual function in patients with complete visual loss due to glaucoma. Investigators in China should identify appropriate priorities in the field of glaucoma based on their medical resources and experience. Equal attention should be given to make sure that the glaucoma practice is high-standard and evidence-based. Glaucoma care should also be accessible, affordable and acceptable (3A criteria) for majority of patients.

Glaucoma management of ambulatory surgery

[Glaucoma Surgery in China: Problems and Solutions].

A 5-Year Clinical Experience of Pediatric Ophthalmic Ambulatory Surgery Under General Anesthesia From a Chinese Tertiary Children's Hospital

Management of peri-operation in anti-glaucoma surgery

Progresses of glaucoma surgery

How to Make an Appropriate Choice of Glaucoma Surgery

The Application of Topical Anesthesia Combinedwith Subconjunctival Anesthesiafor Glaucoma Surgery

China's Overuse of Inpatient Treatment and Routine Preoperative Testing

Glaucoma surgery: what we need to know now for the future?

Cost-Utility Analysis of Minimally Invasive Glaucoma Surgeries for Patients with Mild-to-Moderate Primary Open-Angle Glaucoma in Rural and Urban China

[How to Choose the Appropriate Surgical Approach and Time for Treatment of Blepharoptosis].

Application of UBM in the Pre-and Post-Operative Management of Primary Angle-Closure Glaucoma

Cost-utility analysis of commonly used anti-glaucoma interventions for mild-to-moderate primary open-angle glaucoma patients in rural and urban China

Minimally Invasive Glaucoma Surgery in Primary Angle-Closure Glaucoma

What Should Be Done in Glaucoma Research in China

Application of Cataract Surgery in the Management of Glaucoma

Surgical Management of Chronic Angle-Closure Glaucoma

Topical Anesthesia with Subconjunctival Anesthesia in Anti-Glaucoma Surgery

Trends in operating room-based glaucoma procedures at a single eye center from 2016–2020

Problems Related to Ophthalmic Endoscopic Surgery and Some Strategies for Its Systematic Development into a Precise Procedure

[Ophthalmic Complication and Management of Endoscopic Sinus Surgery].